Skip to content
CrickUpload your file
Back to health matches

Library / health / PNPLA3 I148M — fatty liver risk variant

Default is plain English. Flip to Technical for the original clinical wording.

PNPLA3 I148M — fatty liver risk variant

PNPLA3rs738409gastroenterology
Elevated

One copy of the PNPLA3 I148M risk allele detected.

You have one copy of the PNPLA3 I148M version associated with fatty liver.

One copy of I148M is associated with a modestly increased risk of non-alcoholic fatty liver disease and a meaningfully higher risk of alcohol-related liver disease in regular drinkers. The risk is strongly modified by alcohol intake, body weight, and metabolic health — abstinence and weight management neutralise most of it.

One copy of this DNA change moderately raises your chance of fatty liver — both the kind unrelated to drinking and, more sharply, the kind caused by drinking. The risk is much higher in regular drinkers and people carrying extra weight; cutting back on alcohol and managing weight neutralise most of it.

5 caveats1 population4 references

What this means

PNPLA3 encodes adiponutrin, a lipid-droplet enzyme in liver cells. The I148M variant (rs738409 C>G; p.Ile148Met) reduces the enzyme's ability to remodel lipid droplets, leading to lipid accumulation in hepatocytes. I148M is the strongest common-variant predictor of non-alcoholic fatty liver disease, with a clear gene-dose effect, and it is independently a major risk variant for alcohol-related liver disease: heavy drinkers carrying G alleles progress to cirrhosis at substantially higher rates than non-carriers. Allele frequency varies sharply by ancestry — highest in Latin American populations, which contributes to higher background NAFLD prevalence there. The clinical implication is *interaction*: I148M raises the cost of alcohol intake and of metabolic stress, but does little harm to people who drink little and remain metabolically healthy.

PNPLA3 makes a small enzyme inside liver cells that helps manage the fat droplets stored there. One common DNA change (called I148M) makes the enzyme work less well, so fat builds up in the liver more easily. It is the strongest common DNA change linked to fatty liver disease unrelated to drinking, and — separately — it sharply raises the risk of alcohol-related liver damage in regular drinkers. Frequency varies a lot between populations and is highest in Latin American groups. The key point is that this variant mostly *amplifies* other things going on: drinking and being overweight cost you more if you carry it, and cutting back on either does more good than it would for someone without the variant.

Caveats

  • Risk is heavily modified by alcohol intake — abstinence substantially neutralises the alcohol-related component.
  • Risk is also modified by body weight, metabolic health, and coexisting liver conditions (hepatitis viruses, iron overload).
  • Many G-allele carriers — even homozygotes — never develop clinical liver disease.
  • Allele frequency varies sharply by ancestry; the variant is much more common in Hispanic/Latino populations.
  • A simple blood test (liver enzymes) and ultrasound give the real clinical picture.

Populations

  • Highest frequency in Hispanic/Latino populations; well-studied in European, East Asian, and African ancestries

References